Inhibrx Biosciences, Inc. Total Liabilities
Inhibrx Biosciences, Inc. total liabilities. Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has total liabilities worth $205.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See INBX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Inhibrx Biosciences, Inc. (2016–2025)
Total liabilities of Inhibrx Biosciences, Inc. from 2016 to 2025. This chart illustrates how Inhibrx Biosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Inhibrx Biosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Cixing
SHE:300307
|
China | CN¥1.19 Billion |
|
Integra LifeSciences Holdings
NASDAQ:IART
|
USA | $2.54 Billion |
|
Sdiptech AB (publ)
ST:SDIP-B
|
Sweden | Skr5.69 Billion |
|
AS LHV GROUP EO -10
F:ASU0
|
Germany | €8.89 Billion |
|
Paras Defence and Space Technologies Limited
NSE:PARAS
|
India | Rs2.40 Billion |
|
Meren Energy
ST:MER
|
Sweden | Skr1.25 Billion |
|
Harrow Health Inc
NASDAQ:HROW
|
USA | $401.97 Million |
|
Sino Wealth Electronic Ltd
SHE:300327
|
China | CN¥366.08 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Inhibrx Biosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Inhibrx Biosciences, Inc. asset portfolio.
Liquidity & Leverage Metrics
Inhibrx Biosciences, Inc. Total Liabilities Ratios Explained
Inhibrx Biosciences, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inhibrx Biosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual total liabilities of Inhibrx Biosciences, Inc. from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $138.49 Million | +193.51% |
| 2024-12-31 | $47.18 Million | -82.15% |
| 2023-12-31 | $264.39 Million | +13.56% |
| 2022-12-31 | $232.82 Million | +137.41% |
| 2021-12-31 | $98.07 Million | +43.65% |
| 2020-12-31 | $68.27 Million | -43.14% |
| 2019-12-31 | $120.06 Million | +77.53% |
| 2018-12-31 | $67.63 Million | +70.49% |
| 2017-12-31 | $39.67 Million | +98.00% |
| 2016-12-31 | $20.03 Million | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more